Literature DB >> 1912992

The neuroprotective action of dizocilpine (MK-801) in the rat middle cerebral artery occlusion model of focal ischaemia.

R Gill1, C Brazell, G N Woodruff, J A Kemp.   

Abstract

1. An acute model of focal ischaemia, which involves permanent occlusion of the middle cerebral artery of the rat with 4 h survival, was used to find the minimum effective plasma concentration of dizocilpine (MK-801) and to determine its dose-effect relationship. 2. MK-801 was administered at the time of occlusion and was given as an i.v. bolus followed by an infusion for 4 h to maintain a steady state plasma concentration of the drug throughout the study. MK-801 was given at 3 dose levels; 0.04 mg kg-1 i.v. bolus + 0.6 micrograms kg-1 min-1 infusion; 0.12 mg kg-1 i.v. bolus + 1.8 micrograms kg-1 min-1 infusion; 0.4 mg kg-1 i.v. bolus + 6 micrograms kg-1 min-1 infusion, which gave mean plasma levels over the 4 h of 8.0 ng ml-1, 18.9 ng ml-1 and 113.2 ng ml-1 respectively. 3. MK-801 at 8.0 ng ml-1 gave 10% reduction in the volume of ischaemic brain damage in the cerebral cortex which just reached significance. The middle dose of MK-801 (18.9 ng ml-1) gave a highly significant reduction in the volume of ischaemic brain damage in the cerebral cortex and hemisphere, volumes of ischaemic tissue being reduced by 60% and 50% compared to saline-treated animals, respectively. The highest plasma concentration of MK-801 (113.2 ng ml-1) resulted in a 35% reduction in the volume of hemispheric damage and a 40% reduction in the volume of cortical damage, which were significant.4. The reduction in the amount of protection afforded by the highest dose of MK-801 may be due to the hypotensive effect of this dose. There was no protection against the volume of damage in the caudate nucleus for any of the doses of MK-801 tested.5. Therefore the minimum effective plasma concentration of MK-801 was 8.0 ngml1, although the greatest protection was seen with a plasma level of 18.9 ng ml- 1. This correlates well with the concentration of MK-801 required to block N-methyl-D-aspartate (NMDA) receptors and prevent NMDA receptor mediated neurotoxicity in vitro.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1912992      PMCID: PMC1908204          DOI: 10.1111/j.1476-5381.1991.tb12371.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  41 in total

1.  Correlation between amino acid release and neuropathologic outcome in rat brain following middle cerebral artery occlusion.

Authors:  S P Butcher; R Bullock; D I Graham; J McCulloch
Journal:  Stroke       Date:  1990-12       Impact factor: 7.914

2.  Calcium accumulation by glutamate receptor activation is involved in hippocampal cell damage after ischemia.

Authors:  H Benveniste; M B Jørgensen; N H Diemer; A J Hansen
Journal:  Acta Neurol Scand       Date:  1988-12       Impact factor: 3.209

3.  Effect of the NMDA antagonist MK-801 on local cerebral blood flow in focal cerebral ischaemia in the rat.

Authors:  C K Park; D G Nehls; G M Teasdale; J McCulloch
Journal:  J Cereb Blood Flow Metab       Date:  1989-10       Impact factor: 6.200

4.  Systemic administration of MK-801 protects against ischemia-induced hippocampal neurodegeneration in the gerbil.

Authors:  R Gill; A C Foster; G N Woodruff
Journal:  J Neurosci       Date:  1987-10       Impact factor: 6.167

5.  Calcium uptake evoked by electrical stimulation is enhanced postischemically and precedes delayed neuronal death in CA1 of rat hippocampus: involvement of N-methyl-D-aspartate receptors.

Authors:  P Andiné; I Jacobson; H Hagberg
Journal:  J Cereb Blood Flow Metab       Date:  1988-12       Impact factor: 6.200

6.  Ifenprodil and SL 82.0715 as cerebral anti-ischemic agents. I. Evidence for efficacy in models of focal cerebral ischemia.

Authors:  B Gotti; D Duverger; J Bertin; C Carter; R Dupont; J Frost; B Gaudilliere; E T MacKenzie; J Rousseau; B Scatton
Journal:  J Pharmacol Exp Ther       Date:  1988-12       Impact factor: 4.030

7.  Delayed hippocampal damage in humans following cardiorespiratory arrest.

Authors:  C K Petito; E Feldmann; W A Pulsinelli; F Plum
Journal:  Neurology       Date:  1987-08       Impact factor: 9.910

8.  Quantitative assessment of early brain damage in a rat model of focal cerebral ischaemia.

Authors:  K A Osborne; T Shigeno; A M Balarsky; I Ford; J McCulloch; G M Teasdale; D I Graham
Journal:  J Neurol Neurosurg Psychiatry       Date:  1987-04       Impact factor: 10.154

9.  Protective effect of the glutamate antagonist, MK-801 in focal cerebral ischemia in the cat.

Authors:  E Ozyurt; D I Graham; G N Woodruff; J McCulloch
Journal:  J Cereb Blood Flow Metab       Date:  1988-02       Impact factor: 6.200

10.  Plasma and CSF levels of dizocilpine (MK-801) required for neuroprotection in the quinolinate-injected rat striatum.

Authors:  C L Willis; C Brazell; A C Foster
Journal:  Eur J Pharmacol       Date:  1991-04-24       Impact factor: 4.432

View more
  18 in total

1.  Differential effects of NMDA and AMPA glutamate receptors on functional magnetic resonance imaging signals and evoked neuronal activity during forepaw stimulation of the rat.

Authors:  Willy Gsell; Michael Burke; Dirk Wiedermann; Gilles Bonvento; Afonso C Silva; François Dauphin; Christian Bührle; Mathias Hoehn; Wolfram Schwindt
Journal:  J Neurosci       Date:  2006-08-16       Impact factor: 6.167

2.  Competitive as well as uncompetitive N-methyl-D-aspartate receptor antagonists affect cortical neuronal morphology and cerebral glucose metabolism.

Authors:  R J Hargreaves; M Rigby; D Smith; R G Hill; L L Iversen
Journal:  Neurochem Res       Date:  1993-12       Impact factor: 3.996

Review 3.  Mitochondrial dysfunction induced by nuclear poly(ADP-ribose) polymerase-1: a treatable cause of cell death in stroke.

Authors:  Paul Baxter; Yanting Chen; Yun Xu; Raymond A Swanson
Journal:  Transl Stroke Res       Date:  2013-09-07       Impact factor: 6.829

4.  The effect of chlormethiazole on neuronal damage in a model of transient focal ischaemia.

Authors:  S G Sydserff; A J Cross; K J West; A R Green
Journal:  Br J Pharmacol       Date:  1995-04       Impact factor: 8.739

5.  Lack of effect of L-687,414 ((+)-cis-4-methyl-HA-966), an NMDA receptor antagonist acting at the glycine site, on cerebral glucose metabolism and cortical neuronal morphology.

Authors:  R J Hargreaves; M Rigby; D Smith; R G Hill
Journal:  Br J Pharmacol       Date:  1993-09       Impact factor: 8.739

6.  Neuroprotective profile of lifarizine (RS-87476) in rat cerebrocortical neurones in culture.

Authors:  G R May; W S Rowand; J G McCormack; R D Sheridan
Journal:  Br J Pharmacol       Date:  1995-04       Impact factor: 8.739

7.  Neuroprotective properties of lifarizine compared with those of other agents in a mouse model of focal cerebral ischaemia.

Authors:  C M Brown; C Calder; C Linton; C Small; B A Kenny; M Spedding; L Patmore
Journal:  Br J Pharmacol       Date:  1995-08       Impact factor: 8.739

8.  NADPH oxidase-2: linking glucose, acidosis, and excitotoxicity in stroke.

Authors:  Angela M Brennan-Minnella; Seok Joon Won; Raymond A Swanson
Journal:  Antioxid Redox Signal       Date:  2015-01-10       Impact factor: 8.401

Review 9.  Excitatory amino acid antagonists and their potential for the treatment of ischaemic brain damage in man.

Authors:  J McCulloch
Journal:  Br J Clin Pharmacol       Date:  1992-08       Impact factor: 4.335

10.  Inhibition by lifarizine of intracellular Ca2+ rises and glutamate exocytosis in depolarized rat cerebrocortical synaptosomes and cultured neurones.

Authors:  D C Budd; G R May; D G Nicholls; J G McCormack
Journal:  Br J Pharmacol       Date:  1996-05       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.